Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Daily Feeds
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Cormedix (CRMD)
NASDAQ:CRMD
CRMD Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.03 - $13.85
Previous CloseN/A
Volume1.29M
Average Volume (3M)1.24M
Market Cap
$645.00M
Enterprise Value$429.83M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.88
Next Earnings
Apr 01, 2025EPS Estimate
0.12Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.80
Shares Outstanding60,677,204
10 Day Avg. Volume640,085
30 Day Avg. Volume1,235,476
Standard Deviation0.24
R-Squared0.12
Alpha0.01
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)52.60
Price to Cash Flow (P/CF)-11.80
P/FCF Ratio0.00
Enterprise Value/Market Cap0.67
Enterprise Value/RevenueN/A
Enterprise Value/Gross Profit-2.09K
Enterprise Value/Ebitda-9.11
Forecast
1Y Price Target
$16.00Price Target Upside43.11% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering5
---
Bulls Say, Bears Say
Bulls Say
Market PerformanceThe DefenCath launch continues to outpace expectations, leading to a Market Outperform rating and a risk-adjusted price target.
Revenue GrowthRevenue growth is driven by mid-sized dialysis organizations, with future orders already scheduled for delivery.
Sales PerformanceCRMD reported prelim 4Q24 DefenCath sales of ~$31MM, significantly above Street expectations of $20MM.
Bears Say
Order DelaysThere is a delay in ordering from a large dialysis provider, which is logistical and not related to DefenCath.
Price ErosionVolume growth is expected to be partially offset by price erosion due to increased discounting and rebates.
Stock PressureCRMD shares are under pressure partly due to consolidation after a significant move since mid-August and disappointment with lack of 4Q guidance.
---
Ownership Overview
2.34% Insiders
8.22% Mutual Funds
9.32% Other Institutional Investors
69.26% Public Companies and Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
CRMD FAQ
What was Cormedix’s price range in the past 12 months?
Cormedix lowest stock price was $3.03 and its highest was $13.85 in the past 12 months.
What is Cormedix’s market cap?
Cormedix’s market cap is $645.00M.
When is Cormedix’s upcoming earnings report date?
Cormedix’s upcoming earnings report date is Apr 01, 2025 which is in 39 days.
How were Cormedix’s earnings last quarter?
Cormedix released its earnings results on Oct 30, 2024. The company reported -$0.05 earnings per share for the quarter, beating the consensus estimate of -$0.122 by $0.072.
Is Cormedix overvalued?
According to Wall Street analysts Cormedix’s price is currently Undervalued.
Does Cormedix pay dividends?
Cormedix does not currently pay dividends.
What is Cormedix’s EPS estimate?
Cormedix’s EPS estimate is 0.12.
How many shares outstanding does Cormedix have?
Cormedix has 60,677,204 shares outstanding.
What happened to Cormedix’s price movement after its last earnings report?
Cormedix reported an EPS of -$0.05 in its last earnings report, beating expectations of -$0.122. Following the earnings report the stock price went down -22.513%.
Which hedge fund is a major shareholder of Cormedix?
Currently, no hedge funds are holding shares in CRMD
---
Cormedix Stock Smart Score
Outperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$16.00 (43.11% Upside)
$16.00 (43.11% Upside)
Blogger Sentiment
Bullish
CRMD Sentiment 100%
Sector Average 70%
Sector Average 70%
Insider Transactions
Bought Shares
Worth $15.0K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Neutral
Last 7 Days ▲ 1.1%
Last 30 Days ▼ 0.6%
Last 30 Days ▼ 0.6%
News Sentiment
Neutral
Bullish news 50%
Bearish news 100%
Bearish news 100%
Technicals
SMA
Positive
20 days / 200 days
Momentum
237.61%
12-Months-Change
Fundamentals
Return on Equity
-65.04%
Trailing 12-Months
Asset Growth
-15.14%
Trailing 12-Months
Company Description
Cormedix
CorMedix, Inc. operates as a pharmaceutical and medical device company, which seeks to in-license, develop and commercialize prophylactic and therapeutic products for the prevention and treatment of infectious and inflammatory diseases. The firm is developing its product Neutrolin, a novel, non-antibiotic antimicrobial solution designed to prevent costly and dangerous bloodstream infections associated with the use of central venous catheters. The company was founded by Antony E. Pfaffle in 2006 and is headquartered in Berkeley Heights, NJ.
---
CRMD Earnings Call
Q3 2024
0:00 / 0:00
Earnings Call Sentiment|Neutral
The earnings call demonstrated strong revenue performance and market penetration of DefenCath, along with positive future EBITDA expectations. However, these positives are counterbalanced by increased operating expenses, potential revenue variability, and high customer concentration. Overall, the call reflects a cautiously optimistic outlook with significant achievements and some areas of concern.Read More>---
CRMD Stock 12 Month Forecast
Average Price Target
$16.00
▲(43.11% Upside)
Technical Analysis
Best Analysts Covering CRMD
1 Year
1 Year Success Rate
16/25 ratings generated profit
1 Year Average Return
+38.94%
reiterated a buy rating 2 months ago
Copying Jason Butler's trades and holding each position for 1 Year would result in 64.00% of your transactions generating a profit, with an average return of +38.94% per trade.
---